Parliamentary Search

Written question asked by Lorraine Beavers (Labour) on Thursday, 2 July 2026, in the House of Commons. It was due for an answer on Monday, 6 July 2026. It was answered by Sharon Hodgson (Labour) on Wednesday, 15 July 2026 on behalf of the Department of Health and Social Care.

Metabolic Dysfunction-associated Steatohepatitis

Question

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to integrate steatotic liver disease indicators into non-communicable disease policy and frameworks to meet the World Health Assembly resolution on steatotic liver disease adopted in May 2026.

Answer

The Government recognises the importance of the World Health Assembly’s resolution on steatotic liver disease (SLD), which marks the first time liver disease has been formally recognised as part of the global agenda on noncommunicable diseases.

We are taking action to ensure SLD is integrated within whole-system approaches and tackled effectively. This includes through NHS England’s Liver Transformation Programme, which aims to improve liver disease diagnosis and treatment through focus on the entire care pathway, ensuring a more integrated and effective approach to liver care. The programme has three workstreams, awareness and prevention, detection and diagnosis, and treatment, which will ensure outcomes are aligned with the goals of the World Health Assembly’s resolution on SLD.

Furthermore, the newly published Cardiovascular Disease Modern Service Framework is specifically designed as an integrated cardiovascular-kidney-metabolic strategy and makes specific mention of the importance of addressing metabolic associated SLD.

Secondary information

Type
Written question
Reference
15626
Session
2026-27
Subjects
World Health Assembly Metabolic dysfunction-associated steatohepatitis
Link
View this Written question on www.parliament.uk